Pal, Sumanta K.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,260

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 518

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 515

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., et al. (2015) · Journal for ImmunoTherapy of Cancer

Renal cell carcinoma treatmentImmunotherapy and Immune Responses

Cited by 205

Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors

Salgia, N. J., Bergerot, P. G., Maia, M. C., Dizman, N., Hsu, J., Gillece, J. D., Folkerts, M., Reining, L., Trent, J., Highlander, S. K., et al. (2020) · European Urology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 194

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Ebrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 109

Melanoma and microbiota: Current understanding and future directions

Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 89

STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers

Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research

Immunotherapy and Immune ResponsesProstate Cancer Treatment and Research

Cited by 80

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma

Dizman, N., Hsu, J., Bergerot, P. G., Gillece, J. D., Folkerts, M., Reining, L., Trent, J., Highlander, S. K., & Pal, S. K. (2021) · Cancer Medicine

Probiotics and Fermented FoodsGut microbiota and health

Cited by 78

Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults with Cancer

Hsu, T., Nathwani, N., Loscalzo, M., Chung, V., Chao, J., Karanes, C., Koczywas, M., Forman, S., Lim, D., Siddiqi, T., et al. (2019) · Journal of the American Geriatrics Society

Nursing care and researchCancer survivorship and care

Cited by 60